Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
Solvency ratios for the analyzed period demonstrate a generally improving financial position, though with some fluctuations. Overall, the company appears to be decreasing its reliance on debt financing, with several key ratios indicating a strengthening ability to meet its long-term obligations. However, recent periods show a slight reversal of some positive trends, warranting continued monitoring.
- Debt Levels
- The Debt to Equity ratio decreased from 0.85 in 2021 to 0.63 in 2024, indicating a reduced proportion of debt relative to shareholder equity. A slight increase to 0.74 is observed in 2025. Similar trends are present in the Debt to Capital ratios, declining from 0.46 to 0.39 over the same period, before increasing to 0.42 in 2025. The Debt to Assets ratios also show a consistent decrease from 0.37 to 0.32 in 2024, with a subsequent rise to 0.36 in 2025. Inclusion of operating lease liabilities results in slightly higher ratios, but the trends remain consistent.
- Leverage
- Financial Leverage, which represents total assets divided by total equity, decreased from 2.33 in 2021 to 1.96 in 2024, suggesting a diminishing reliance on financial leverage. This trend reverses slightly in 2025, with the ratio increasing to 2.07. This indicates a moderate increase in the use of leverage.
- Coverage Ratios
- Interest Coverage, measuring the company’s ability to meet its interest obligations, experienced a significant decline from 17.49 in 2021 to 5.54 in 2023. While it recovered somewhat to 6.03 in 2024 and 6.12 in 2025, it remains substantially lower than the initial value. Fixed Charge Coverage followed a similar pattern, decreasing from 12.19 to 4.61 in 2023, then showing modest improvement to 5.01 and 5.04 in 2024 and 2025 respectively. The declines in coverage ratios, despite decreasing debt levels, suggest a potential decrease in operating profitability or an increase in fixed charges other than interest.
In summary, the company demonstrated improving solvency through 2024, characterized by decreasing debt ratios and leverage. However, the slight increases in debt ratios and the relatively low, though stabilizing, coverage ratios in 2025 suggest a need for continued monitoring of both debt management and operational performance.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term obligations and current maturities of long-term obligations | ||||||
| Long-term obligations, excluding current maturities | ||||||
| Total debt | ||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity1 | ||||||
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Equity, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity = Total debt ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio for the analyzed period demonstrates a generally decreasing trend, indicating a strengthening financial position with respect to leverage. Initial values show a ratio of 0.85 in 2021, followed by a reduction to 0.78 in 2022 and a further decrease to 0.75 in 2023. This downward trajectory continues into 2024, reaching a low of 0.63. However, the most recent year, 2025, exhibits a slight increase, bringing the ratio to 0.74.
- Total Debt
- Total debt remained relatively stable between 2021 and 2023, fluctuating around US$34.5 billion. A decrease is observed in 2024, with total debt falling to US$31.3 billion. The final year, 2025, shows an increase in total debt to US$39.4 billion, contributing to the slight rise in the debt to equity ratio.
- Total Shareholders’ Equity
- Total shareholders’ equity consistently increased throughout the analyzed period. Starting at US$40.8 billion in 2021, it grew to US$43.98 billion in 2022, US$46.74 billion in 2023, US$49.58 billion in 2024, and reached US$53.41 billion in 2025. This consistent growth in equity is a primary driver of the decreasing debt to equity ratio observed in the earlier years.
- Debt to Equity Ratio Trend
- The initial decline in the debt to equity ratio from 2021 to 2024 suggests a reduction in financial risk, as the proportion of debt financing relative to equity financing decreased. The increase in the ratio in 2025, while modest, warrants monitoring to determine if it represents a temporary fluctuation or the beginning of a new trend. The overall trend indicates a generally conservative capital structure.
The observed changes suggest a company prioritizing equity financing or experiencing increased profitability leading to retained earnings growth, which in turn boosts shareholders’ equity. The increase in debt in 2025, coupled with the slight increase in the debt to equity ratio, could be due to strategic investments, acquisitions, or other financing activities that require additional borrowing.
Debt to Equity (including Operating Lease Liability)
Thermo Fisher Scientific Inc., debt to equity (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term obligations and current maturities of long-term obligations | ||||||
| Long-term obligations, excluding current maturities | ||||||
| Total debt | ||||||
| Operating lease liabilities (included in Other accrued expenses) | ||||||
| Operating lease liabilities (included in Other long-term liabilities) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Equity (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio, including operating lease liability, demonstrates a generally decreasing trend over the five-year period. Total debt remained relatively stable between 2021 and 2023, while shareholders’ equity consistently increased. This combination resulted in a declining ratio during this timeframe. A more significant decrease occurred between 2023 and 2024, followed by a slight increase in the most recent year.
- Debt to Equity Ratio Trend
- The ratio began at 0.89 in 2021 and decreased to 0.66 in 2024. This indicates a strengthening of the company’s financial position with respect to debt relative to equity during those years. The increase to 0.76 in 2025 suggests a moderate shift, potentially due to increased debt financing or a slower growth rate in equity.
- Total Debt
- Total debt exhibited relative stability from 2021 to 2023, fluctuating within a narrow range. A decrease was observed in 2024, falling to US$32,775 million, before rising again to US$40,855 million in 2025. This 2025 increase represents the largest single-year change in total debt over the observed period.
- Shareholders’ Equity
- Shareholders’ equity consistently increased throughout the period, moving from US$40,793 million in 2021 to US$53,407 million in 2025. This consistent growth in equity contributed significantly to the declining debt to equity ratio observed between 2021 and 2024.
The observed trends suggest a period of decreasing financial leverage followed by a potential re-introduction of debt financing in the latest year. The increase in the debt to equity ratio in 2025 warrants further investigation to understand the underlying reasons and potential implications for the company’s financial risk profile.
Debt to Capital
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term obligations and current maturities of long-term obligations | ||||||
| Long-term obligations, excluding current maturities | ||||||
| Total debt | ||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | ||||||
| Total capital | ||||||
| Solvency Ratio | ||||||
| Debt to capital1 | ||||||
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Capital, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio for the analyzed period demonstrates a generally decreasing trend, followed by a slight increase in the most recent year. Total debt fluctuates over the five-year period, while total capital consistently increases, contributing to the observed ratio behavior.
- Debt to Capital Ratio Trend
- The debt to capital ratio decreased from 0.46 in 2021 to 0.39 in 2023, indicating a diminishing proportion of debt financing relative to total capital. This suggests a strengthening of the capital structure through either debt reduction or capital increases. However, in 2024, the ratio increased slightly to 0.42, potentially due to an increase in total debt or a slower growth rate in total capital.
- Total Debt
- Total debt remained relatively stable between 2021 and 2023, fluctuating within a narrow range. A decrease is observed in 2024, with the value reaching 31,275 US$ millions. The final year, 2025, shows a notable increase in total debt to 39,385 US$ millions, which is the highest value recorded during the analyzed period.
- Total Capital
- Total capital exhibits a consistent upward trend throughout the period, increasing from 75,663 US$ millions in 2021 to 92,792 US$ millions in 2025. This consistent growth in capital base likely contributes to the initial decline in the debt to capital ratio, despite fluctuations in total debt.
The increase in the debt to capital ratio in 2025 warrants further investigation. While the overall trend suggests improving solvency, the recent increase in debt relative to capital should be monitored to assess any potential risks associated with increased leverage.
Debt to Capital (including Operating Lease Liability)
Thermo Fisher Scientific Inc., debt to capital (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term obligations and current maturities of long-term obligations | ||||||
| Long-term obligations, excluding current maturities | ||||||
| Total debt | ||||||
| Operating lease liabilities (included in Other accrued expenses) | ||||||
| Operating lease liabilities (included in Other long-term liabilities) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | ||||||
| Total capital (including operating lease liability) | ||||||
| Solvency Ratio | ||||||
| Debt to capital (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Capital (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio, inclusive of operating lease liabilities, demonstrates a generally decreasing trend over the observed period, with a slight increase in the most recent year. Total debt and total capital both increased throughout the period, but capital grew at a faster rate for most of the timeframe.
- Debt to Capital Ratio Trend
- The ratio decreased from 0.47 in 2021 to 0.40 in 2024, indicating a strengthening capital structure and reduced reliance on debt financing relative to equity and other capital sources. However, in 2025, the ratio increased to 0.43, suggesting a shift back towards greater debt utilization.
- Total Debt Evolution
- Total debt remained relatively stable between 2021 and 2023, fluctuating around US$36 billion. A notable decrease was observed in 2024, with debt falling to US$32.775 billion. This decrease was followed by a substantial increase in 2025, reaching US$40.855 billion, potentially due to new financing activities or acquisitions.
- Total Capital Evolution
- Total capital exhibited a consistent upward trend from 2021 to 2025. It increased from US$77.132 billion in 2021 to US$94.262 billion in 2025. The growth rate in capital appears to have outpaced the growth in debt for the majority of the period, contributing to the initial decline in the debt to capital ratio.
The increase in the debt to capital ratio in 2025 warrants further investigation to understand the underlying drivers, such as the nature of the debt incurred and its impact on future financial flexibility. The overall trend suggests a generally conservative capital structure, though recent developments indicate a potential change in financial leverage.
Debt to Assets
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term obligations and current maturities of long-term obligations | ||||||
| Long-term obligations, excluding current maturities | ||||||
| Total debt | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets1 | ||||||
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Assets, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio for the analyzed period demonstrates a generally stable financial position with some fluctuation. Over the five-year period, the ratio exhibits a slight downward trend initially, followed by an increase in the most recent year.
- Overall Trend
- The debt-to-assets ratio began at 0.37 in 2021 and decreased to 0.32 in 2024. However, it increased to 0.36 in 2025. This indicates a moderate level of financial leverage throughout the period, with a slight reduction in reliance on debt financing until the final year.
- Year-over-Year Changes
- From 2021 to 2022, the ratio decreased from 0.37 to 0.35, suggesting a reduction in debt relative to assets. A similar ratio of 0.35 was maintained from 2022 to 2023, indicating stability in the capital structure. The most significant change occurred between 2023 and 2024, with a decrease to 0.32, likely due to asset growth outpacing debt. The ratio then increased to 0.36 in 2025, coinciding with an increase in total debt.
- Debt and Asset Movements
- Total debt remained relatively consistent between 2021 and 2023, fluctuating within a narrow range. A decrease was observed in 2024, followed by a notable increase in 2025. Total assets generally increased throughout the period, with a more substantial rise between 2024 and 2025. The interplay between these movements explains the observed fluctuations in the debt-to-assets ratio.
The observed changes suggest the entity has managed its debt levels effectively, maintaining a moderate degree of leverage. The increase in the ratio in 2025 warrants further investigation to determine the reasons for the increased debt and its potential impact on future financial performance.
Debt to Assets (including Operating Lease Liability)
Thermo Fisher Scientific Inc., debt to assets (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term obligations and current maturities of long-term obligations | ||||||
| Long-term obligations, excluding current maturities | ||||||
| Total debt | ||||||
| Operating lease liabilities (included in Other accrued expenses) | ||||||
| Operating lease liabilities (included in Other long-term liabilities) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Assets (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt to assets ratio, including operating lease liability, exhibited relative stability over the five-year period, with some fluctuation. Total debt remained consistently between US$32.775 billion and US$40.855 billion, while total assets increased overall. This resulted in a generally decreasing, then stabilizing, ratio.
- Debt to Assets Ratio Trend
- The ratio began at 0.38 in 2021, decreased to 0.37 in both 2022 and 2023, then further decreased to 0.34 in 2024. A slight increase to 0.37 was observed in 2025. This suggests an initial improvement in the company’s solvency position, followed by a stabilization as assets grew more rapidly than debt.
Total debt experienced a minor decrease from 2021 to 2022, followed by a slight increase in 2023. A more substantial decrease occurred in 2024, before increasing significantly in 2025. This suggests potential strategic shifts in financing or capital expenditure during those periods.
- Asset Growth
- Total assets demonstrated a consistent upward trend, increasing from US$95.123 billion in 2021 to US$110.343 billion in 2025. The most significant increase occurred between 2024 and 2025, contributing to the stabilization of the debt to assets ratio in the final year.
The combination of fluctuating debt levels and increasing assets indicates a dynamic capital structure. While the debt to assets ratio remained within a narrow range, the underlying changes in both debt and asset values warrant further investigation to understand the drivers behind these movements.
- Overall Solvency
- The debt to assets ratio consistently remained below 0.40 throughout the period, suggesting a moderate level of financial leverage. The decrease in the ratio from 2021 to 2024 indicates a strengthening solvency position, although the increase in 2025 should be monitored.
Financial Leverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Total assets | ||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Financial leverage1 | ||||||
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Financial Leverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Financial Leverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Financial leverage = Total assets ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
An examination of the financial information reveals a generally decreasing trend in financial leverage over the observed period, followed by a slight increase in the most recent year. Total assets exhibited a consistent increase from 2021 to 2023, a slight decrease in 2024, and a substantial increase in 2025. Simultaneously, total shareholders’ equity demonstrated consistent growth throughout the entire period.
- Financial Leverage
- The financial leverage ratio decreased from 2.33 in 2021 to 1.96 in 2024, indicating a diminishing reliance on debt financing relative to equity. This suggests an improvement in the company’s solvency position over these years. However, the ratio increased slightly to 2.07 in 2025, potentially due to increased debt or a slower growth rate in equity compared to asset expansion. The overall trend suggests a strengthening financial structure, though the 2025 value warrants further investigation.
The consistent growth in shareholders’ equity, coupled with the initial decline in financial leverage, indicates that the company has been effectively financing its asset growth through retained earnings and potentially new equity issuance. The substantial increase in total assets in 2025, alongside a modest increase in leverage, suggests that a larger proportion of this asset growth was funded by debt or other liabilities compared to previous years. This shift could be related to strategic investments or acquisitions undertaken during that period.
In summary, the company demonstrated improving solvency from 2021 to 2024, as evidenced by the decreasing financial leverage. The slight increase in leverage in 2025, coinciding with a significant asset expansion, suggests a potential change in financing strategy that should be monitored in future periods.
Interest Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Thermo Fisher Scientific Inc. | ||||||
| Add: Net income attributable to noncontrolling interest | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Solvency Ratio | ||||||
| Interest coverage1 | ||||||
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Interest Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Interest Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
The interest coverage ratio demonstrates a declining trend from 2021 to 2023, followed by a period of stabilization and slight improvement. This indicates a changing ability to meet interest obligations from operating earnings.
- Earnings Before Interest and Tax (EBIT)
- EBIT decreased from US$9,373 million in 2021 to US$7,614 million in 2023, representing a substantial reduction. Subsequently, EBIT experienced a recovery, increasing to US$8,385 million in 2024 and further to US$8,687 million in 2025. Despite this recovery, EBIT in 2025 remains below the level recorded in 2021.
- Interest Expense
- Interest expense consistently increased throughout the analyzed period. Starting at US$536 million in 2021, it rose to US$726 million in 2022, then significantly to US$1,375 million in 2023. The rate of increase slowed in 2024 and 2025, with interest expense reaching US$1,390 million and US$1,419 million respectively.
- Interest Coverage Ratio
- The interest coverage ratio, calculated as EBIT divided by interest expense, decreased considerably from 17.49 in 2021 to 5.54 in 2023. This decline reflects the combination of decreasing earnings and increasing interest expense. The ratio showed modest improvement in 2024, reaching 6.03, and continued to increase slightly to 6.12 in 2025. While the ratio stabilized, it remains significantly lower than the value observed in 2021, suggesting a reduced margin of safety in covering interest obligations.
The observed trend suggests that while the company has begun to recover its earnings, the increasing interest expense continues to exert pressure on its ability to comfortably cover its interest obligations. The stabilization of the interest coverage ratio in the later years indicates that the relationship between earnings and interest expense is becoming more balanced, but continued monitoring is warranted.
Fixed Charge Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Thermo Fisher Scientific Inc. | ||||||
| Add: Net income attributable to noncontrolling interest | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Add: Operating lease costs | ||||||
| Earnings before fixed charges and tax | ||||||
| Interest expense | ||||||
| Operating lease costs | ||||||
| Fixed charges | ||||||
| Solvency Ratio | ||||||
| Fixed charge coverage1 | ||||||
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Fixed Charge Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Fixed Charge Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
The company’s fixed charge coverage exhibited a declining trend from 2021 to 2023, followed by a stabilization in the subsequent two years. Earnings before fixed charges and tax decreased initially, then showed signs of recovery, while fixed charges consistently increased throughout the period.
- Earnings Before Fixed Charges and Tax
- Earnings before fixed charges and tax decreased from US$9,627 million in 2021 to US$7,969 million in 2023, representing a decline of approximately 17.2%. A subsequent recovery is observed, with earnings increasing to US$8,738 million in 2024 and further to US$9,068 million in 2025. This suggests a potential stabilization and improvement in the company’s ability to cover its fixed obligations following the initial decline.
- Fixed Charges
- Fixed charges demonstrated a consistent upward trend throughout the analyzed period. Starting at US$790 million in 2021, they increased to US$1,077 million in 2022, US$1,730 million in 2023, US$1,743 million in 2024, and reached US$1,800 million in 2025. This continuous increase in fixed charges places greater pressure on the company’s earnings to maintain adequate coverage.
- Fixed Charge Coverage
- The fixed charge coverage ratio decreased significantly from 12.19 in 2021 to 4.61 in 2023. This substantial decline indicates a weakening ability to meet fixed obligations with available earnings. The ratio stabilized in 2024 and 2025, reaching 5.01 and 5.04 respectively. While the ratio has ceased its decline, it remains considerably lower than the level observed in 2021, suggesting a sustained, though stabilized, reduction in the margin of safety regarding fixed charge coverage.
The combination of decreasing earnings (initially) and increasing fixed charges contributed to the observed decline in fixed charge coverage. The recent stabilization in coverage is attributable to the recovery in earnings, offsetting the continued rise in fixed charges. Continued monitoring of both earnings and fixed charge levels is recommended to assess the sustainability of this stabilization.